Skip to content

Comparison of usefulness of two drug combination Nadifloxacin and Benzoyl peroxide with another two drug combination Adapalene and Benzoyl Peroxide in pimple

Efficacy and safety of Nadifloxacin and Benzoyl peroxide versus Adapalene and Benzoyl Peroxide in acene vulgaris : A Randomized open label phase IV clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/08/009280
Enrollment
34
Registered
2017-08-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris Health Condition 2: null- Mild to moderate cases of Acne vulgaris

Interventions

Intervention1: Adapalene and Benzoyl Peroxide: All enrolled subjects will be instructed to apply a thin layer of the study medications over the lesions
benzoyl peroxide 2.5% gel once daily at bedtime and Adapalene 0.1% cream twice daily. The patients will be instructed to apply the study medications at least 10 minutes after the skin is gently washed
benzoyl peroxide 2.5% gel once daily at bedtime and nadifloxacin 1% gel twice daily. The patients will be instructed to apply the study medications at least 10 minutes after the skin is gently washed,

Sponsors

Dr Arijit Ghosh
Lead Sponsor
Dr Kapildev Das
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of 12 to 40 years of age of either sex with >= 2 but <= 30 total lesions - inflammatory (papules and pustules) and/or non-inflammatory (open and closed comedones) lesions in the face which correspond to a baseline investigator global assessment (IGA) score of 2 or 3 (both inclusive)

Exclusion criteria

Exclusion criteria: 1. Age out of range, total lesion count 30, severe acne, 2. Subjects regularly using any anti-acne medications in the last 30 days before study entry 3. Subjects with nodulo-cystic lesions, acne conglobata, acne fulminans, secondary acne (e.g. chloracne, drug-induced acne) 4. Any acne requiring systemic treatment

Design outcomes

Primary

MeasureTime frame
Change in the total lesion count - both inflammatory and non-inflammatory lesions.Timepoint: 12 weeks

Secondary

MeasureTime frame
Change in investigator global assessment and Cardiff acne disability indexTimepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Arijit Ghosh

Malda Medical College

drarijitghosh@gmail.com9874727137

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026